Drugs / Aquaphor
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01135290 | Jun → Oct 2010 | — | Healthpoint | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02534129 | Aug 2015 → Mar 2016 | radiodermatitis | ProTechSure Scientific, Inc. | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00162747 | Dec 2001 → Jun 2005 | skin disorder | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04865731 Comparator | Jun 2022 → Jun 2024 | head and neck cancer | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aquaphor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02534129 ↗ |
| Route | Topical | “Topical treatment with sunflower seed oil (SSO) or Aquaphor® reduced sepsis and neonatal mortality in hospitalized preterm infants <33 weeks' gestational age in Bangladesh.” PMID 34039435 ↗ May 2021 |